BPC-157 is on the FDA's Category 2 bulks list. It is still widely sold
Category 2 identifies substances raising significant safety risks, which may not be used in 503A compounding. BPC-157 has no human efficacy trials.
The FDA's 503A bulk drug substances lists signal whether a substance may be used in compounding. Category 1 substances may be used while under evaluation. Category 2 substances have been identified as raising significant safety risks and may not be.
BPC-157 sits in Category 2 and has no human efficacy trials. It continues to be sold widely, generally under "research use only" labelling — which states the product is not for human use. That is a legal position, not a safety finding.
Where every peptide in this category actually sits: peptides ranked by evidence.
Filed by the Transparent Peptide research desk. Corrections: the corrections log.